long intergenic non-protein coding RNA 1467Genealiases: []
Q-omics provides the consensus-scored LINC01467 profile across patient tissues and cancer cell-line models. LINC01467 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01467 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, LINC01467 RNA expression shows 6,128 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, HNSC, and STAD as cancer lineages where LINC01467 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01467 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01467 survival associations across molecular data types. LINC01467 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01467 RNA expression–survival associations across cancer types. High LINC01467 expression shows unfavorable associations in BLCA, UCEC, ACC, PRAD, PAAD and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01467 RNA expression.
This table summarizes LINC01467 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01467. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01467 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, LUSC and COAD. The HNSC box plot shows higher LINC01467 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .025).
This table shows molecular features associated with LINC01467 in patient tissues and cancer cell lines. In patient samples, LINC01467 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
